Efficacy and tolerance of aranoza combined with topotecan against transplantable lung cancer on mice

New nitro urea anticancer drug aranoza (Ar) was administered simultaneously with topotecan (T) to BDF1 mice bearing s.c. Lewis lung carcinoma (LLC) or Balb/c nude mice bearing human s.c. lung cancer xenografts RL4 (cell line A549). T was injected with doses of 0.5; 0.75; 1.0 or 2.0 mg/kg 3 times daily or 2.5; 5.0; 10.0 mg/kg on day 2 after LLC transplantation. The same it was for T dose range of 0.5 mg/kg 2 times on days 2 and 4 after RL4 inoculation. For Ar, dose range was the following: of 100 or 200 mg/kg 3 times daily after LLC inoculation or 100 mg/kg 2 times on days 2 and 4 after RL4 inoculation. All drugs were given i.p. Synergism of TAr was demonstrated in comparison with monotherapy of T and Ar. The therapeutic efficacy and tolerance of TAr in comparison with standard second-line monotherapy T were evaluated.